Connect with us

Finance

Senolytics, a new anti-aging therapeutic, taking on Humira and Enbrel

Published

on


cancer cells
Cancer
cells in tissue culture from human connective tissue, illuminated
by darkfield amplified contrast, at a magnification of
500x

Wikimedia
Commons


  • A new
    anti-aging therapeutic
    in the clinical pipeline could stand
    to disrupt multibillion-dollar
    legacy franchises
    like AbbVie’s Humira and Amgen’s
    Enbrel. 
  • This new type of therapeutic, called
    senolytics
    , is being developed by four biotech companies
    right now, and analysts think the first market-ready product
    could become available as early as 2023. 
  • Senolytics will be able to target all age-related
    diseases, eliminating the need for current therapeutics that
    are more limited in the range of diseases they can
    address. 

A new therapeutic treatment might be making its way to the
anti-aging market, and it could stand to disrupt
multibillion-dollar franchises like AbbVie’s Humira and Amgen’s
Enbrel. 

According to a report from analysts at Citi GPS, many biotech
companies are investing in developing senolytics, a new type of
treatment to combat all aging-related disease.

These drugmakers include Unity
Biotechnology
, Oisin Biotechnologies, Siwa Therapeutics, and
Google venture Calico. The first commercially available
treatment could be here by 2023, according to the Citi
report, but a proof of concept could be available as early
as next year. …



Sponsored: 


If you enjoyed reading this story so
far, why don’t you join Business Insider
PRIME? Business Insider provides visitors from MSN with a
special offer.  




Simply
click here to claim your deal and get access to all exclusive
Business Insider PRIME benefits.



Continue Reading
Advertisement Find your dream job

Trending